Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. - Asthma: reduces the frequency of wheezing, shortness of breath and nighttime symptoms in patients requiring long‑term control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy watery eyes caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity, improving exercise tolerance.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Neuropsychiatric events including mood changes or suicidal thoughts - Hepatic enzyme elevation - Severe skin reactions like Stevens‑Johnson syndrome - Blood dyscrasias (e.g., eosinophilia, neutropenia) - Severe rash or urticaria

Patients and prescribers should consider several safety measures when using Montelukast Sandoz. - Monitor liver function: assess baseline enzymes and repeat if clinically indicated. - Assess for neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid use in individuals with known hypersensitivity to Montelukast or any tablet excipients. - Consider alternative therapy during pregnancy if risk outweighs benefit. - Store at ambient temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) – may increase Montelukast plasma levels. - Concurrent use of other leukotriene antagonists – provides no additional benefit and may raise adverse‑event risk. - Phenobarbital (strong CYP inducer) – may markedly lower Montelukast exposure.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole) – modestly increase drug concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce therapeutic effect. - Selective serotonin reuptake inhibitors – may heighten neuropsychiatric side‑effect risk.